Clinical trial NCT03592225: Can an Educational Intervention Targeting General Practitioners Increase HPV Vaccination Coverage in AuRA_Lyon (France)
Official title: Prevention At PRImary CAre Level - Increasing HPV Vaccination in Lyon.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Human Papillomavirus Vaccination
Keywords: General Practitioners
France
RCT
HPV vaccination
Lead sponsor: International Agency for Research on Cancer
Sponsor class: OTHER
First posted: 2018-07-19
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 groups of General practitioners are randomized to be allocated either in the intervention group or the control group
Primary purpose: OTHER

Brief summary: The PAPRICA implementation trial aims to test the efficacy of an educational intervention about HPV vaccination and targeting general practitioners in Lyon

Detailed description: The PAPRICA study aims to test if an intervention directed to General Practitioners (GP) to train them in methods for recommending HPV vaccine with greater confidence and efficiency is effective to increase HPV vaccination coverage in France. As each health professional is associated in France to a specific reference number i.e. "RPPS number", RPPS numbers for all General Practitioners (GP) from the city of Lyon will be randomly allocated either to the intervention arm or to the control arm to ensure that each arm contains 50% of the total number of GPs. After allocation, GPs in the allocation arm will be identified and invited to attend the intervention i.e. a 3-hour workshop at IARC in the presence of HPV vaccination specialists. The effect of the intervention on the HPV vaccination coverage in Lyon will be measured through HPV vaccines reimbursement data extracted from the Inter-Scheme National Information System within the National Health Insurance System (SNIIR-AM : Système National d'Information Inter-Régimes de l'Assurance Maladie ). Linkable data between girls and General Practitioners (GP) via RPPS numbers will allow us to allocate girls either in the intervention or the control arm. Vaccination coverage will be estimated within each of these cohorts.

Eligibility criteria: Inclusion Criteria:

* general practitioners (GP) from Lyon (69001-69009) from private practice

Exclusion Criteria:

Primary outcomes:
measure: Assessing change from baseline HPV vaccination coverage of Lyon's girls aged 11-14 obtained by the GP from the intervention arm at 18 months after the intervention (increase in number of vaccinated girls as assessed by questionnaire in the study cohort)
timeFrame: 18 months
Secondary outcomes:
measure: Assessing change from baseline in GP's attitude and knowledge towards HPV vaccination 1 month after receiving the intervention
timeFrame: 1 month
Other outcomes:
measure: 3. Assessing change from control group in mothers and girls' attitude and knowledge towards HPV vaccination 18 months after the intervention
timeFrame: 18 months
Locations:
city: Lyon
country: France
facility: International Agency for Research on Cancer (IARC)
Study officials:
affiliation: IARC, WHO
name: PATRICIA VILLAIN, PhD
role: PRINCIPAL_INVESTIGATOR
References: